- Home
- SPT vs AKRO Comparison
SPT vs AKRO Comparison
Compare SPT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- AKRO
- Stock Information
- Founded
- SPT 2010
- AKRO 2017
- Country
- SPT United States
- AKRO United States
- Employees
- SPT N/A
- AKRO N/A
- Industry
- SPT Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- AKRO Health Care
- Exchange
- SPT Nasdaq
- AKRO Nasdaq
- Market Cap
- SPT 1.1B
- AKRO 3.9B
- IPO Year
- SPT 2019
- AKRO 2019
- Fundamental
- Price
- SPT $21.20
- AKRO $51.77
- Analyst Decision
- SPT Buy
- AKRO Strong Buy
- Analyst Count
- SPT 13
- AKRO 6
- Target Price
- SPT $31.69
- AKRO $82.50
- AVG Volume (30 Days)
- SPT 598.6K
- AKRO 1.7M
- Earning Date
- SPT 07-31-2025
- AKRO 08-08-2025
- Dividend Yield
- SPT N/A
- AKRO N/A
- EPS Growth
- SPT N/A
- AKRO N/A
- EPS
- SPT N/A
- AKRO N/A
- Revenue
- SPT $418,413,000.00
- AKRO N/A
- Revenue This Year
- SPT $12.32
- AKRO N/A
- Revenue Next Year
- SPT $11.90
- AKRO N/A
- P/E Ratio
- SPT N/A
- AKRO N/A
- Revenue Growth
- SPT 17.79
- AKRO N/A
- 52 Week Low
- SPT $18.52
- AKRO $21.02
- 52 Week High
- SPT $39.75
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SPT 49.75
- AKRO 48.51
- Support Level
- SPT $19.88
- AKRO $51.08
- Resistance Level
- SPT $21.63
- AKRO $57.35
- Average True Range (ATR)
- SPT 0.62
- AKRO 2.17
- MACD
- SPT 0.10
- AKRO -0.82
- Stochastic Oscillator
- SPT 72.73
- AKRO 8.17
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.